Home Compliance At Large: Why Didn’t Novartis Try to Conceal its Ongoing Bribery? ComplianceFCPANews At Large: Why Didn’t Novartis Try to Conceal its Ongoing Bribery? July 30, 2020 29 Share FacebookLinkedinTwitter Taljat David | Shutterstock You must be a Paid or Free Trial Member to Access this Content. Paid members, please login to view your news subscription(s). RELATED ARTICLESMORE FROM AUTHOR Compliance Selfish Foreign Policy Reasons, Not Altruism, Is Why Congress Enacted The FCPA Compliance Snyder v. United States: Will Public Servants Be Next to Put Out a Tip Jar? Compliance When Advocacy Turns Into Obstruction: A Cautionary Tale for Corporate Counsel Handling Gov’t Investigations